Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012632 | 0.86 | ADRB2 (0.49) | ADRB2HTR2AGBA1FNTAFNTB | |
| SCHEMBL3941219 | 0.86 | ADRB2 (0.49) | ADRB2HTR2AGBA1FNTAFNTB | |
| SCHEMBL13072252 | 0.85 | ADRB2 (0.46) | ADRB2SPHK1BCDIN3DGBA1FNTA | |
| SCHEMBL13596185 | 0.81 | ADRB2 (0.71) | ADRB2 | |
| SCHEMBL18539226 | 0.81 | GBA1 (0.50) | GBA1FNTAFNTBAAK1 | |
| SCHEMBL28442139 | 0.78 | ALDH1A1 (0.45) | ADRB2BCDIN3DGBA1FNTAFNTB | |
| SCHEMBL14832179 | 0.74 | SPHK1 (0.47) | ADRB2SPHK1SIGMAR1 | |
| SCHEMBL27765030 | 0.73 | KMT2A (0.45) | ADRB2HTR2ASIGMAR1OPRM1OPRD1 | |
| SCHEMBL28219424 | 0.73 | ADRB2 (0.49) | ADRB2SPHK1 | |
| SCHEMBL27486404 | 0.73 | HTT (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | ADRB1, ADRB2, ADRB3 | ADRB2 2/4885SPHK1 518/4885HTR2A 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.